Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

Boguniewicz, Mark; Beck, Lisa A.; Sher, Lawrence; Guttman‐Yassky, Emma; Thaçi, Diamant; Blauvelt, Andrew; Worm, Margitta; Corren, Jonathan; Soong, Weily; Lio, Peter; Rossi, Ana B.; Lü, Yuan; Chao, Jingdong; Eckert, Laurent; Gadkari, Abhijit; Hultsch, T.; Ruddy, Marcella; Mannent, Leda; Graham, Neil M.H.; Pirozzi, Gianluca; Chen, Zhe; Ardeleanu, Marius

doi:10.1016/j.jaip.2020.12.059

Cited by 38 publications

(36 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Boguniewicz et al. (2021) reported that dupilumab improved asthma and/or chronic sinonasal conditions in adult patients with moderate-to-severe AD by analyzing the data obtained from four randomized, double-blinded, placebo-controlled trials.…”

Section: Impact Of Dupilumab On Comorbidities and Disease Burden Of Admentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Impact Of Dupilumab On Comorbidities and Disease Burden Of Admentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

show abstract

“…Asthma, AD and CRSwNP are inflammatory diseases among subgroups that share common pathophysiological mechanisms which explain their frequent co-existence ( 1 , 2 ). Targeting the key drivers of Type 2 inflammation has a therapeutic effect on both AD, asthma and CRSwNP ( 12 , 33 , 34 ). Furthermore, biologics have been shown to reduce the need for OCS in patients with severe asthma, CRSwNP and AD ( 12 , 16 ).…”

Section: Discussionmentioning

confidence: 99%

“…Participants viewed facilitated access to biological therapies and funding of emollients as possible solutions for disappointing outcomes and high therapy costs. A recent study demonstrated the concurrent efficacy of Dupilumab in AD, asthma and chronic sinonasal conditions, however, the question of whether a unique therapy could lead to a concomitant improvement of all the aforementioned diseases still remains to be further investigated ( 2 , 33 ). Multiple data already exist showing an improvement in asthma after treatment of CRSwNP and vice versa ( 1 , 2 , 7 , 12 ), supporting the link between upper and lower airway diseases ( 5 , 36 ).…”

Section: Discussionmentioning

confidence: 99%

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Prins

Raap²,

Mueller³

et al. 2022

Front. Allergy

View full text Add to dashboard Cite

BackgroundType 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases.AimsTo improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future.MethodologyThis qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach.ResultsEighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the need for alternatives to sinus surgery, whereas patients with asthma requested better medical care to prevent exacerbations and patients with AD would warmly welcome the reimbursement of emollients.ConclusionPatients with asthma, CRSwNP and AD have shared unmet needs that need to be addressed by physicians, the academic community and health policy makers. This survey provides unique recommendations made by patients for the implementation of better care.

show abstract

“…Type 2 immune responses are pathogenic in allergic disorders such as atopic dermatitis and asthma [15,24,25]. In a murine asthma model using repeated ovalbumin administration, OX40 deficiency resulted in a significant reduction of airway hyperreactivity and Th2 responses such as IL-4 and IgE production [26].…”

Section: Ox40-ox40l Axis In Type 1 and Type 2 Immune Responsesmentioning

confidence: 99%

OX40L–OX40 Signaling in Atopic Dermatitis

Furue

Furue²

2021

JCM

View full text Add to dashboard Cite

OX40 is one of the co-stimulatory molecules expressed on T cells, and it is engaged by OX40L, primarily expressed on professional antigen-presenting cells such as dendritic cells. The OX40L–OX40 axis is involved in the sustained activation and expansion of effector T and effector memory T cells, but it is not active in naïve and resting memory T cells. Ligation of OX40 by OX40L accelerates both T helper 1 (Th1) and T helper 2 (Th2) effector cell differentiation. Recent therapeutic success in clinical trials highlights the importance of the OX40L–OX40 axis as a promising target for the treatment of atopic dermatitis.

show abstract

Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

Cited by 38 publications

References 54 publications

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

OX40L–OX40 Signaling in Atopic Dermatitis

Contact Info

Product

Resources

About